About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 68681 record(s)
Req # A-2019-001924
Adverse Reaction Report (AER) for Mesalazine. Report numbers: E2B_02776457, 000730742, 000730734.Organization: Health Canada
June 2020
Req # A-2019-002012
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-122779-892, OVERVIEW OF CANNABIS PRODUCTS PERMITTED FOR SALE.Organization: Health Canada
June 2020
Req # A-2019-002027
Adverse Reaction Report (AER). Report number: 000733211.Organization: Health Canada
June 2020
Req # A-2019-002081
Adverse Reaction Report (AER). Report numbers: E2B_02893727, E2B_02895533, E2B_02916646.Organization: Health Canada
June 2020
Req # A-2020-000005
Adverse Reaction Report (AER) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02266424, E2B_02502592, E2B_02263289, E2B_02569479, E2B_02521865.Organization: Health Canada
June 2020
Req # A-2020-000034
Adverse Reaction Report (AER). Report number: E2B_02876672.Organization: Health Canada
June 2020
Req # A-2020-000051
Adverse Reaction Report (AER) for ENTYVIO. Report numbers: E2B_02968814, E2B_02935743, E2B_02935720, E2B_02980774, E2B_02928576, E2B_02931979, E2B_02928948, E2B_02971530, E2B_02982966, E2B_02935644, E2B_02955576, E2B_02987178.Organization: Health Canada
June 2020
Req # A-2020-000052
Adverse Reaction Report (AER) for VEDOLIZUMAB. Report numbers: E2B_02959635, E2B_02972254, E2B_02931989, E2B_02965282, E2B_02983115, E2B_02973212, E2B_02940189, E2B_02975948, E2B_02928892.Organization: Health Canada
June 2020
Req # A-2020-000087
Adverse Reaction Report (AER). Report number: 000730668.Organization: Health Canada
June 2020
Req # A-2020-000190
Adverse Reaction Report (AER) for Teriflunomide. Report number: E2B_02548709.Organization: Health Canada
June 2020